Pancreatic Cancer Study Reaches 10,000 Participants Worldwide
The PRECEDE Consortium doubles its enrollment target to 20,000 as it builds a dataset for early detection tool development.
Category: Pancreatic
Pancreatic
Latest
Pancreatic
Latest
A New Liquid Biopsy Test for Early Pancreatic Cancer Detection
PharusDx announced a liquid biopsy test that uses microRNA and CA19-9 biomarkers to detect early-stage pancreatic cancer.
Pancreatic
Latest
Pancreatic Cystic Neoplasm Study to Include Immunovia NGS Test
Immunovia has been selected for a US-government-funded study to evaluate biomarker tests for monitoring pancreatic cystic neoplasms.
Artificial Intelligence Predicts Future Pancreatic Cancer
An artificial intelligence tool has successfully identified those at the highest risk for pancreatic cancer up to 3 years before diagnosis.
Read More
PDACatch an FDA Breakthrough Device for Pancreatic Cancer Detection
Singlera Genomics’ PDACatch assay is a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.
Read More
Biomarkers Show Promise for Finding Pancreatic Cancer Risk Early
A research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.
Read More
Bluestar Genomics Commercializes Pancreatic Cancer Test
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Read More
New Genetic Culprit Suspected of Pancreatic Cancer Onset
New research points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.
Read More
Bluestar Genomics’ Pancreatic Cancer Detection Test Achieves High Sensitivity & Specificity
Bluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test. Â
Read More
Pancreatic Cancer Could be Diagnosed up to Three Years Earlier
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.
Read More
Bluestar Genomics Receives CAP Accreditation for its Clinical Lab
The CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.Â
Read More
PancreaSeq Molecular Test Outperforms Current Guidelines
The PancreaSeq molecular test accurately classifies pancreatic cysts as potentially cancerous or benign, a large, multi-center study found.
Read More
Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers
Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.
Read More
Researchers Discover Molecular Switch in Pancreatic Cancer that Triggers Metastasis
Pancreatic ductal adenocarcinoma affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate under 10%.
Read More
Stool Sample Microorganisms Could Help Detect Pancreatic Cancer Early
Researchers have found a molecular signature in stool samples that could predict whether patients are at high risk of pancreatic cancer.
Read More
Researchers May Have Found Diagnostic Game Changer for Pancreatic Cancer
Yale Cancer Center early detection research is providing new reason for optimism for the diagnosis of pancreatic cancer.
Read More
Liquid Biopsy Test Detects Pancreatic Cancer Signal
Bluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.
Read More
Blood Test May Be Future of Pancreatic Cancer Detection
New research showed that blood tests may be the future of pancreatic cancer detection. Pancreatic cancer is one of the most deadly forms of the disease.
Read More